Srinivasa R. Nagalla

Srinivasa R. Nagalla

Auto-generated profile, based on publicly available information

Srinivasa R. Nagalla

DiabetOmics, Inc, Hillsboro, OR, USA

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1996 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YOYoungman Oh
Youngman Oh
SNSrinivasa R. Nagalla
Srinivasa R. Nagalla
YYYoshitaka Yamanaka
Yoshitaka Yamanaka
HKHo-Seong Kim
Ho-Seong Kim
EWElizabeth Wilson
Elizabeth Wilson
RRRon G. Rosenfeld
Ron G. Rosenfeld
The mac25 cDNA was originally cloned from leptomeningial cells and subsequently reisolated through differential display as a sequence preferentially expressed in senescent human mammary epithelial cells. The deduced amino acid sequence of the human mac25 propeptide shares a 20-25% identity to human insulin-like growth factor-binding proteins (IGFBPs), suggesting that mac25 could be another member of the IGFBP family. In the present study, we have generated recombinant human mac25 (rh-mac25) in a baculovirus expression system and assessed its affinity for IGFs and have evaluated the pattern of expression of the mac25 gene in human tissues. Binding of 125I-IGF-I and 125I-IGF-II to rh-mac25 was demonstrated by Western ligand blotting after nondenaturing polyacrylamide gel electrophoresis and by affinity cross-linking with as little as 2 nM rh-mac25. Specificity of rh-mac25 binding to 125I-IGFs was demonstrated by competition for rh-mac25 binding with unlabeled IGFs, but not with [QAYLL]IGF-II analog, which has 100-fold less affinity for IGFBPs. In comparison with IGFBP-3, rh-mac25 has at least a 5-6-fold lower affinity for IGF-I and 20-25-fold lower affinity for IGF-II. mac25 mRNA was detectable in a wide range of normal human tissues, with decreased expression in breast, prostate, colon, and lung cancer cell lines. In conclusion, mac25 specifically binds IGFs and constitutes a new member of the IGFBP family, IGFBP-7. Its wider distribution in normal tissue and lower expression in several cancer cells indicate that IGFBP-7 may function as a growth-suppressing factor, as well as an IGF-binding protein.

2 January 2009 in Journal of Proteome Research
Verified
Journal Article
Closed access
PRPaturi V. Rao
Paturi V. Rao
ARAshok P. Reddy
Ashok P. Reddy
XLXinfang Lu
Xinfang Lu
SDSurendra Dasari
Surendra Dasari
AKAdiraju Krishnaprasad
Adiraju Krishnaprasad
SNSrinivasa R. Nagalla
Srinivasa R. Nagalla

3 March 2005 in Journal of Proteome Research
Verified
Journal Article
Closed access
BSBrian Searle
Brian Searle
SDSurendra Dasari
Surendra Dasari
PWPhillip A. Wilmarth
Phillip A. Wilmarth
MTMark Turner
Mark Turner
ARAshok P. Reddy
Ashok P. Reddy
SNSrinivasa R. Nagalla
Srinivasa R. Nagalla

1 January 1993
Verified
Book Chapter
Closed access
ESEliot R. Spindel
Eliot R. Spindel
EGEliezer Giladi
Eliezer Giladi
TSThomas P. Segerson
Thomas P. Segerson
SNSrinivasa Nagalla
Srinivasa Nagalla

1 September 2013 in Obstetrics & Gynecology
Verified
Journal Article
Closed access
JRJuha P. Rasanen
Juha P. Rasanen
CSCaryn K. Snyder
Caryn K. Snyder
PRPaturi V. Rao
Paturi V. Rao
RMRaluca Mihalache
Raluca Mihalache
SHSeppo Heinonen
Seppo Heinonen
SNSrinivasa R. Nagalla
Srinivasa R. Nagalla
To evaluate the potential clinical utility of serum biomarkers for first-trimester prediction of gestational diabetes mellitus (GDM). Maternal serum concentrations of glycosylated (Sambucus nigra lectin-reactive) fibronectin, adiponectin, sex hormone-binding globulin, placental lactogen, and high-sensitivity C-reactive protein (CRP) were measured at 5-13 weeks of gestation in a case-control study of 90 pregnant women with subsequent development of GDM and in 92 control group participants. Ability to detect GDM was assessed using logistic regression modeling and receiver operating characteristic (ROC) curves. Classification performance and positive and negative predictive values were reported at specific thresholds. Glycosylated fibronectin variation across trimesters was evaluated using a serial-measures analysis of 35 nondiabetic control group participants. First-trimester serum concentrations of glycosylated fibronectin, adiponectin, high-sensitivity CRP, and placental lactogen were significantly associated (P<.001) with GDM. After adjustment for maternal factors and other biomarkers, glycosylated fibronectin demonstrated an independent association with GDM (P<.001). Adiponectin, high-sensitivity CRP, and placental lactogen demonstrated modest classification performance compared with glycosylated fibronectin (respectively: area under the curve [AUC] 0.63; 95% confidence interval [CI] 0.53-0.71; AUC 0.68; 95% CI 0.60-0.76; and AUC 0.67, 95% CI 0.59-0.75; compared with AUC 0.91; 95% CI 0.87-0.96). Glycosylated fibronectin levels above a threshold of 120 mg/L correctly identified 57 GDM case group participants with a positive predictive value of 63% (95% CI 53-72%) and a negative predictive value of 95% (95% CI 94-95%) at a population prevalence of 12%. There was no association between sex hormone-binding globulin and GDM. First-trimester glycosylated fibronectin is a potential pregnancy-specific biomarker for early identification of women at risk for GDM. II.

1 January 2015 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JRJuha Rasanen
Juha Rasanen
MQMatthew J. Quinn
Matthew J. Quinn
ALAmber Laurie
Amber Laurie
EBEric Bean
Eric Bean
CRCharles T. Roberts
Charles T. Roberts
MGMichael G. Gravett
Michael G. Gravett